Why Genetic Testing Can Be a Game Changer in Mental Health Care
Photo by Sangharsh Lohakare on Unsplash
In psychiatry and psychopharmacology, one of the biggest challenges is the “trial-and-error” nature of prescribing: patients may try multiple medications over many weeks or months, experiencing side effects or inadequate response before a suitable drug (and dose) is found. Genetic testing—especially pharmacogenetic (PGx) panels such as those offered by Genomind—aims to shorten that guesswork by providing clinicians with individualized genomic data relevant to drug metabolism, receptor sensitivity, and neurotransmitter pathways.
For example, the Genomind PGx test analyzes genes implicated in pharmacokinetics (how your body processes a drug) and pharmacodynamics (how a drug acts on its target) to help predict which medications may be more or less effective, or carry higher risk of adverse effects. (Genomind) For example, if a patient carries a variant in a CYP450 enzyme indicating slower metabolism of an antidepressant, the clinician might choose a lower starting dose or an alternative drug less reliant on that pathway.
Clinical studies support that PGx-guided prescribing can improve outcomes. In a meta-analysis of randomized controlled trials in major depressive disorder, patients who received PGx-guided treatment had higher odds of remission (pooled RR favoring PGx) and improved response rates versus treatment-as-usual. (Genomind) Naturalistic studies also suggest that clinicians who employ such testing often change prescribing decisions and may reduce side effect burden. (PMC) In one study, patients whose physicians incorporated genetic testing had 40% fewer ER visits and 58% fewer psychiatric hospitalizations in the subsequent six months compared to controls. (Genomind)
That said, the field is still evolving, and not all clinicians are convinced. Some caution that for many patients, genetic test results may not fully explain treatment response, and that evidence is not yet robust for all populations or disorders. (Psychiatric Times)
Ethical, Privacy, and Safety Considerations
While genetic testing offers valuable insights, it’s important to understand that it is not the right choice for everyone. At Áureo, we take privacy and informed consent seriously. All genetic samples and reports are processed through CLIA- and CAP-certified laboratories that adhere to HIPAA and federal genetic information nondiscrimination laws (GINA), ensuring your health data remains protected and confidential. Still, patients should be aware that genetic information—like any medical data—has implications for privacy, insurance, and family members who may share similar genetic traits. Before testing, we review these ethical and security considerations thoroughly so patients can make an informed choice. For some individuals, particularly those who prefer not to have their genetic data stored or shared electronically, traditional lab-based assessments and lifestyle-based interventions may be a safer and equally effective path. Genetic testing can be a powerful tool when used appropriately, but it should always be optional, transparent, and centered on the patient’s comfort and consent.
At Aureo, we integrate Genomind testing into a holistic, patient-centered workflow:
Ordering the test
After an initial intake and clinical history—including past medication trials, side effect profiles, and comorbidities—our provider can order the Genomind PGx panel (or equivalent) from a CLIA/CAP-certified lab. The patient provides a simple cheek-swab sample (or saliva), which is shipped for processing. (Genomind)Clinical consultation & result interpretation
Once results are back (typically within a few weeks), we schedule a detailed genetic consultation. Our team reviews the report with the patient, explaining responsible interpretation (what can and cannot be inferred), and mapping gene-drug interactions to their existing or planned medications. We look not only at the “red-flag” genes (where a drug is best avoided) but also at more subtle guidance (e.g. dose adjustment, metabolic risk).Integrated treatment planning
Genetic results do not replace clinical judgment, but rather become one tool in a multi-modal plan. We combine them with lab testing, metabolic monitoring, nutritional support, somatic treatments, psychotherapy, and lifestyle interventions. Over time, we re-evaluate and may reorder or update genetic panels if new variants become clinically actionable.
Beyond classic pharmacogenetics, we also consider nutrigenetic / metabolic gene variants such as MTHFR (methylenetetrahydrofolate reductase). Certain polymorphisms (e.g. C677T, A1298C) may lead to reduced enzyme activity, higher homocysteine levels, and altered methylation that can affect mood, cognition, and response to folate derivatives. (PMC) In such cases, clinicians may supplement with L-methylfolate, B12 (methylated form), or other cofactors in a personalized regimen. Some data suggest that patients with these variants derive particular benefit from targeted nutritional and methylation support as adjuncts to psychotropics.
Furthermore, genetic variation in exercise response, lipid metabolism, or antioxidant capacity may help tailor nutritional, fitness, and lifestyle prescriptions to enhance mental health outcomes (though this is a frontier area).
In sum, Genomind and similar genetic testing tools offer a promising lever for precision psychiatry—when used thoughtfully, in context, and as one pillar of integrative, individualized care. In our practice at Aureo, we use it not to dictate treatment, but to inform, refine, and accelerate each patient’s path to mental wellness.
References:
Bousman CA, et al. Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials. Pharmacogenomics. 2019;20(1):37-47. doi:10.2217/pgs-2018-0142
Brennan FX, Gardner KR, Lombard J, Perlis RH, Fava M, Harris HW, Scott R. A naturalistic study of the effectiveness of pharmacogenetic testing to guide treatment in psychiatric patients with mood and anxiety disorders. Prim Care Companion CNS Disord. 2015;17(2). doi:10.4088/PCC.14m01717
Perlis RH, Mehta R, Edwards AM, Tiwari A, Imbens GW. Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: a propensity-score matched study. Depress Anxiety. 2018;35(10):946-952. doi:10.1002/da.22742
Wan L, Huang Y, Zhang Y, et al. Methylenetetrahydrofolate reductase and psychiatric diseases: a comprehensive review. Front Psychiatry. 2018;9:506. doi:10.3389/fpsyt.2018.00506
Gilbody S, et al. Methylenetetrahydrofolate reductase (MTHFR) genetic variants and psychiatric disorders: a meta-analysis. Am J Epidemiol. 2007;165(1):1-12.
Written by Dr. Lindsay Wilkinson ND, LAc
Dr. Lindsay Wilkinson, ND, is a compassionate naturopathic doctor dedicated to empowering her patients to achieve optimal health and well-being. With a focus on integrative medicine, she combines evidence-based treatments with holistic approaches to address a wide range of health concerns. Dr. Wilkinson's passion lies in guiding her patients toward balanced wellness through personalized care and support.